YOLFTbeta
Bls Pharmaceuticals Limited

Bls Pharmaceuticals Limited

BLS · AU · Healthcare / Biotechnology

0.855AUD-0.05 (-5.52%)

Price History

Full chart

Market Stats

Previous Close0.905
Open0.90
Day Range0.855 – 0.90
52-Week Range0.33 – 1.30
Volume249.50K
Market Cap235.28M
P/E (TTM)14.57
Forward P/E0.00
EPS0.07
Dividend Yield0.00%
Beta0.65
50-Day Avg1.01
200-Day Avg0.7379

About

BLS Pharmaceuticals Limited manufactures, imports, exports, and supplies controlled drugs and prescription medicines in Australia, the United Kingdom, Europe, and Japan. It operates through Manufacture/Sales Australia, Plant Based/UK/EU/JPN/AUS, and Wholesale PCC/USA segments. The Manufacture/Sales Australia segment engages in the manufacture and wholesale supply of preventive and novel medicines, cannabis, psilocybin, and MDMA under BLS. The Plant Based/UK/EU/JPN/AUS segment manufactures and distributes consumer health and novel food products under the Dr Watson brand. The Wholesale PCC/USA segment is involved in wholesale of patented Probiotics for gastrointestinal health and immunity. It also provides contract manufacturing services; and storage and distribution services. The company was formerly known as Bioxyne Limited and changed its name to BLS Pharmaceuticals Limited in June 2026. BLS Pharmaceuticals Limited is headquartered in Sydney, Australia

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Samuel Watson
  • HeadquartersLevel 5, Sydney, NSW, Australia, 2000, Australia
  • Websitehttps://blspharma.com

Leadership

  • Mr. Samuel WatsonCEO, MD & Executive Director
  • Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICDCFO & Company Secretary · b. 1953
  • Mr. Jason HineCOO & Executive Director
  • Macdarragh O'NeillHead of Production of GMP & Director of BLS Wholesalers Pty

Financials

Income Statement

Currency: AUD2022-06-302023-06-302024-06-302026-06-30
Total Revenue2.42M5.16M9.33M74.16M
Growth (%)-+113.57%+80.70%+695.33%
Cost of Revenue1.13M3.26M5.93M32.60M
Gross Profit1.29M1.90M3.40M41.56M
Gross Margin53.33%36.79%36.44%56.04%
Operating Expense1.55M4.04M5.06M25.76M
Operating Income-257.62K-2.14M-1.66M15.80M
Operating Margin-10.66%-41.44%-17.79%21.31%
EBITDA--2.05M-1.66M17.00M
EBITDA Margin--39.77%-17.79%22.93%
Net Income-236.51K-1.96M-13.33M15.40M
Net Income Margin-9.79%-38.07%-142.90%20.76%
R&D--717.60K-
R&D as % of Total Revenue--7.70%-
Interest Expense582--460.00K
Interest Expense % of Total Revenue0.02%--0.62%

Balance Sheet

Currency: AUD2022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets2.92M17.69M6.70M-52.08M
Total Liabilities981.51K2.69M3.40M-21.00M
Total Equity1.89M15.14M3.61M-31.09M
Cash2.17M3.85M1.03M-13.29M

Cash Flow

Currency: AUD2022-06-302023-06-302024-06-302026-06-30
Financing Cash Flow-947.17K1.21M3.76M
Capital Expenditure5.79K58.64K492.66K3.46M
Free Cash Flow429.23K-1.19M-4.09M1.95M

Key Statistics & Ratios

Market Cap235.28M
Enterprise Value239.43M
Trailing P/E14.57
Forward P/E0.00
Price / Sales3.18
Price / Book7.86
EPS0.07
Book Value0.135
Revenue (TTM)73.91M
Gross Profit (TTM)39.48M
EBITDA20.13M
Profit Margin20.83%
Operating Margin22.60%
Return on Equity71.30%
Return on Assets34.10%
Shares Outstanding230.66M
Shares Float75.35M
Beta0.65
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jun 24, 20261:10
  • Mar 18, 20121:20